FMP
uniQure N.V.
QURE
NASDAQ
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
4.67 USD
-0.04 (-0.857%)
About
ceo
Mr. Matthew Craig Kapusta
sector
Healthcare
industry
Biotechnology
website
https://www.uniqure.com
exchange
NASDAQ
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzhe...
CIK
0001590560
ISIN
NL0010696654
CUSIP
N90064101
Address
Paasheuvelweg 25a
Phone
31 20 240 6000
Country
NL
Employee
480
IPO Date
Feb 5, 2014
Summary
CIK
0001590560
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
N90064101
ISIN
NL0010696654
Country
NL
Price
4.67
Beta
0.95
Volume Avg.
994.99k
Market Cap
223.4M
Shares
-
52-Week
4.61-22.48
DCF
-0.94
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.72
P/B
-
Website
https://www.uniqure.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest QURE News
It looks like there's no news available.
